Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma

Código QR

Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma

Guardado en:

Detalles Bibliográficos
Autores principales:	Guangbing Xiong, Hua Huang, Mengyu Feng, Gang Yang, Suli Zheng, Lei You, Lianfang Zheng, Ya Hu, Taiping Zhang, Yupei Zhao
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/0aa79ed7b2eb4bdf9fa4a378474b95e9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma
por: Jinsheng Ding, et al.
Publicado: (2021)

Blood small extracellular vesicles derived miRNAs to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
por: Shiwei Guo, et al.
Publicado: (2021)

Advances in Pancreatic Ductal Adenocarcinoma Treatment
por: Eric M. Anderson, et al.
Publicado: (2021)

Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects
por: Ke-Yu Li, et al.
Publicado: (2020)

Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma.
por: Ole Helm, et al.
Publicado: (2014)

CircMYOF triggers progression and facilitates glycolysis via the VEGFA/PI3K/AKT axis by absorbing miR-4739 in pancreatic ductal adenocarcinoma
por: Dandan Zheng, et al.
Publicado: (2021)

Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma
por: Alexander G. Raufi, et al.
Publicado: (2021)

Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma
por: Iranzu González-Borja, et al.
Publicado: (2021)

Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma
por: Imteyaz Ahmad Khan, et al.
Publicado: (2021)

ATG4B Inhibitor UAMC-2526 Potentiates the Chemotherapeutic Effect of Gemcitabine in a Panc02 Mouse Model of Pancreatic Ductal Adenocarcinoma
por: Farnaz Sedigheh Takhsha, et al.
Publicado: (2021)

miR-509-5p and miR-1243 increase the sensitivity to gemcitabine by inhibiting epithelial-mesenchymal transition in pancreatic cancer
por: Hidekazu Hiramoto, et al.
Publicado: (2017)

KRAS-related noncoding RNAs in pancreatic ductal adenocarcinoma
por: Shuang-Ni Yu, et al.
Publicado: (2016)

Splice variants as novel targets in pancreatic ductal adenocarcinoma
por: Jun Wang, et al.
Publicado: (2017)

Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma.
por: Kimberly A Kelly, et al.
Publicado: (2008)

Identifying the neck margin status of ductal adenocarcinoma in the pancreatic head by multiphoton microscopy
por: Jian Xu, et al.
Publicado: (2017)

The lncRNA MALAT1 acts as a competing endogenous RNA to regulate KRAS expression by sponging miR-217 in pancreatic ductal adenocarcinoma
por: Pingping Liu, et al.
Publicado: (2017)

Gα15 in early onset of pancreatic ductal adenocarcinoma
por: Giulio Innamorati, et al.
Publicado: (2021)

Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma.
por: Luigi Laghi, et al.
Publicado: (2012)

Cancer-associated fibroblast heterogeneity is associated with organ-specific metastasis in pancreatic ductal adenocarcinoma
por: Xingyi Pan, et al.
Publicado: (2021)

Diabetes in Humans Activates Pancreatic Stellate Cells via RAGE in Pancreatic Ductal Adenocarcinoma
por: Chiaki Uchida, et al.
Publicado: (2021)

MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance
por: Amy S. Farrell, et al.
Publicado: (2017)

Renalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinoma.
por: Yasheen Gao, et al.
Publicado: (2021)

Prognostic Value of CT Radiomic Features in Resectable Pancreatic Ductal Adenocarcinoma
por: Farzad Khalvati, et al.
Publicado: (2019)

TPH1 and 5-HT<sub>7</sub> Receptor Overexpression Leading to Gemcitabine-Resistance Requires Non-Canonical Permissive Action of EZH2 in Pancreatic Ductal Adenocarcinoma
por: Prakash Chaudhary, et al.
Publicado: (2021)

Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis
por: Shuo Yu, et al.
Publicado: (2021)

CCL2 produced by pancreatic ductal adenocarcinoma is essential for the accumulation and activation of monocytic myeloid‐derived suppressor cells
por: Haitao Gu, et al.
Publicado: (2021)

Dynamic perfusion CT – A promising tool to diagnose pancreatic ductal adenocarcinoma
por: Zaborienė Inga, et al.
Publicado: (2021)

Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma
por: Sachie Kiryu, et al.
Publicado: (2021)

Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance
por: Kostas Palamaris, et al.
Publicado: (2021)

Robust deep learning model for prognostic stratification of pancreatic ductal adenocarcinoma patients
por: Jie Ju, et al.
Publicado: (2021)

Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers—Is There Anything in Sight?
por: Monika Kapszewicz, et al.
Publicado: (2021)

The Potential of Induced Pluripotent Stem Cells to Advance the Treatment of Pancreatic Ductal Adenocarcinoma
por: Ricki T. Krog, et al.
Publicado: (2021)

Potential Prognostic Biomarkers of OSBPL Family Genes in Patients with Pancreatic Ductal Adenocarcinoma
por: Cheng-Wei Chou, et al.
Publicado: (2021)

eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma
por: Karina Chan, et al.
Publicado: (2019)

Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma
por: Michelle R. Goulart, et al.
Publicado: (2021)

Intron retention is a robust marker of intertumoral heterogeneity in pancreatic ductal adenocarcinoma
por: Daniel J. Tan, et al.
Publicado: (2020)

CCAT2 is an oncogenic long non-coding RNA in pancreatic ductal adenocarcinoma
por: Cai,Yi, et al.
Publicado: (2018)

Pancreatic collision tumor of ductal adenocarcinoma and neuroendocrine tumor—A rare case report
por: Prajna Das, et al.
Publicado: (2021)

Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinoma
por: Marie-Claire Rittmann, et al.
Publicado: (2021)

Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review
por: Hong-Bo Li, et al.
Publicado: (2021)